Accéder au contenu
Merck
Toutes les photos(1)

Documents

SML2104

Sigma-Aldrich

Ambrisentan

≥98% (HPLC)

Synonyme(s) :

(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C22H22N2O4
Numéro CAS:
Poids moléculaire :
378.42
Numéro MDL:
Code UNSPSC :
41121706
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Activité optique

[α]/D +160 to +190°, c = 0.5 in methanol

Couleur

white to beige

Solubilité

DMSO: 2 mg/mL, clear

Température de stockage

2-8°C

Chaîne SMILES 

CC1=CC(C)=NC(O[C@@H](C(C2=CC=CC=C2)(OC)C3=CC=CC=C3)C(O)=O)=N1

InChI

1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)

Clé InChI

OUJTZYPIHDYQMC-UHFFFAOYSA-N

Actions biochimiques/physiologiques

Ambrisentan is an endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It is 200-fold selective for the the ETA receptor subtype with a Ki of 1 nM for ETA and a Ki of 195 nM for ETB.

Pictogrammes

Health hazard

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Repr. 1A

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Belinda N Rivera-Lebron et al.
Therapeutic advances in respiratory disease, 11(6), 233-244 (2017-04-21)
Pulmonary arterial hypertension (PAH) is a progressive disease defined by an elevation in pulmonary arterial pressure that can lead to right heart failure and death. Ambrisentan is a selective endothelin receptor antagonist approved for the treatment of idiopathic, heritable PAH
Johanna Weiss et al.
European journal of pharmacology, 660(2-3), 298-304 (2011-04-20)
The safety and effectiveness of drugs used to treat chronic diseases critically depend on their propensity to interact with co-administered drugs. Induction of enzymes and drug transporters involved in the clearance and distribution of drugs may critically reduce exposure with
James A Angus et al.
European journal of pharmacology, 804, 111-116 (2017-03-17)
Endothelin receptor antagonists are approved for pulmonary arterial hypertension. Development of selective ET Human isolated pulmonary (i.d. 5.5mm) and human radial (i.d. 3.23mm) artery ring segments were mounted in organ baths for isometric force measurement. Single concentration-contraction curves to endothelin-1
Sanah M Nkadimeng et al.
Scientific reports, 10(1), 22314-22314 (2020-12-20)
Prevalence of major depression in people with chronic heart failure is higher than in normal populations. Depression in heart failure has become a major issue. Psilocybin-containing mushrooms commonly known as magic mushrooms, have been used since ancient times for their
Ilenia Masi et al.
Cell reports, 34(9), 108800-108800 (2021-03-04)
Cancer cells use actin-based membrane protrusions, invadopodia, to degrade stroma and invade. In serous ovarian cancer (SOC), the endothelin A receptor (ETAR) drives invadopodia by a not fully explored coordinated function of β-arrestin1 (β-arr1). Here, we report that β-arr1 links

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique